Acute Respiratory Distress Syndrome Clinical Trial
— PHYSIO_PRONEOfficial title:
Physiological Study of Prone Position in Acute Respiratory Failure Syndrome
ARDS is an acutely induced respiratory failure characterized by the appearance of bilateral alveolar opacities on imaging and hypoxemia Etiologies are divided into two classes: pulmonary, including all infectious pathologies, aspiration pneumonia, and drowning, and extra-pulmonary, induced by sepsis or acute pancreatitis. The mortality rate of ARDS remains high in unselected patient populations Among strategies that have proven beneficial in terms of patient outcome, prone positioning (PP) is associated with the greatest impact in terms of reduction in mortality. PP is currently recommended in the European guidelines for ARDS associated with a PaO2/FiO2 ratio < 150 mmHg in patients in whom ventilatory settings have been optimized beforehand, The failure of early PP studies to demonstrate a survival benefit in ARDS was attributed to insufficient session duration. The PROSEVA study was the first to demonstrate that a PP duration of 17 h is associated with a reduction in mortality During the COVID-19 pandemic, several centers have reported the implementation of longer PP sessions. Two strategies have emerged from these studies. In one case, the patient was left in the prone position until the criteria for stopping PP were met. Thus, the PP/supine position alternation was completely suppressed. In another published strategy, PP sessions were maintained for a period covering two nights. Furthermore, in a multicenter retrospective study, PP sessions were maintained until clinical improvement was associated with reduced mortality. In this study of 263 patients, the median duration of PP in the extended duration group was 40 h, and 75% of the sessions lasted 48 h or less. Using a propensity score, the authors showed that patients treated with an extended PP duration had a lower 3-month mortality rate than patients in the standard duration group . This protocol was also associated with a 29% cumulative incidence of pressure sores, similar to the 25% cumulative incidence reported in the PROSEVA study Other data published on pressure sores and PP of duration > 24 hours are also reassuring. Finally, a recent review recently reported that an extended PP session of > 24 h had also been used before the COVID-19 pandemic. PP sessions had a median duration of 47-78 hours and were applied mainly to ARDS secondary to community-acquired pneumonia. All pre-COVID studies were retrospective, monocentric, without a control group.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | May 18, 2025 |
Est. primary completion date | January 18, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patient with with ARDS with a P/F ratio < 150 mm Hg regardless of etiology - invasive ventilated patient - indication for DV placement determined by the treating practitioner - BMI= 18 kg/m² - Affiliated to social security Exclusion Criteria: - Patients who have already undergone two prone position sessions - Pregnant women - Refusal to participate in the research - Patients under guardianship and trusteeship - Patients under State Medical Assistance (AME) - Uncontrolled intracranial hypertension - Unstable spinal fracture - Hemodynamic instability defined by MAP < 65 mmHg - Presence of a pacemaker - Presence of an implantable defibrillator - Unresolved pneumothorax or bronchopleural fistula |
Country | Name | City | State |
---|---|---|---|
France | Louis Mourier Hospital | Colombes |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Distribution of intra-pulmonary ventilation volumes during PP sessions maintained until clinical improvement and for a maximum of 48 hours. | The primary endpoint is the center of lung ventilation measured by the EIT between H+16 and before return in the supine position.
This index approximates the proportion of ventilation attributable to the dorsal pulmonary units. It is calculated as follows: CVP(%)= ((?Z at the level of dorsal pulmonary units)*100)/(?Z in the whole lung) Where CVP means the center of alveolar ventilation and ?Z means the variation in electrical impedance during the ventilatory cycle. |
EITmeasurements between H+16 and before return in the supine position | |
Secondary | Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of the percentage, of the percentage of over-distended pulmonary units | The evaluation end point is the percentage of overdistended alveoli and is defined as overdistended pixels on the image produced by the EIT, i.e. as pixels being aerated at the end of expiration but not ventilated, | EITmeasurements between H+16 and before return in the supine position | |
Secondary | Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of the percentage of pulmonary units opening and closing with each respiratory cycle | The evaluation end point is the percentage of pixels opening and closing cyclically at each inspiratory cycle, i.e. pixels ventilated but not aerated at the end of expiration. | EITmeasruements between H+16 and before return in the supine position | |
Secondary | Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of the percentage of collapsed pulmonary units | The evaluation end point is the percentage of pixels opening and closing cyclically The evaluation end point is the percentage of pixels for which the variation in electrical impedance is less than 10% of the maximum variation found among all pixels during a respiratory cycle. | EIT measurements between H+16 and before return in the supine position | |
Secondary | Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of percentage of recruitable pulmonary units | The evaluation end point is the percentage of recruitable pixels will be estimated using the regional ventilation delay (RVD) index as defined in Wriggle et al 2008 CCM and corresponding to : RVD= t_10%*?Z/?t Where t_10% is the time in seconds required to reach 10% of the maximum variation in electrical impedance of the pixel considered for a respiratory cycle, ?Z is the maximum variation in electrical impedance during the respiratory cycle and ?t is the time in seconds of the inspiratory cycle. | EIT measurements between H+16 and before return in the supine position | |
Secondary | Evaluation of the association between prolonged PP duration and the incidence of pressure sores | Pressure sores will be assessed daily for as long as the indication for PP ventilation persists. In the event of pressure sores, their grade will be assessed using the Revised Pressure Injury Staging System. | The last day in ICU |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |